The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDGL | +106.85% | +239.23% | +27.67% | +4,193% |
| S&P | +18.37% | +110.18% | +16.02% | +217% |
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $212.80M | 1353.8% |
| Gross Profit | $203.36M | 1380.6% |
| Gross Margin | 95.56% | 1.7% |
| Market Cap | $6.72B | 12.5% |
| Market Cap / Employee | $12.73M | 0.0% |
| Employees | 528 | 40.4% |
| Net Income | -$42.28M | 72.2% |
| EBITDA | -$46.83M | 71.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $191.19M | -61.7% |
| Accounts Receivable | $79.23M | 1048.4% |
| Inventory | 63.5 | 797.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $122.90M | 4.6% |
| Short Term Debt | $1.05M | 88.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.65% | 46.1% |
| Return On Invested Capital | -90.37% | -6.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$47.05M | 65.2% |
| Operating Free Cash Flow | -$47.05M | 65.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.95 | 8.66 | 9.66 | 9.45 | 44.37% |
| Price to Sales | 60.08 | 37.57 | 23.06 | 13.04 | -96.82% |
| Price to Tangible Book Value | 5.99 | 8.71 | 9.72 | 9.51 | 44.46% |
| Enterprise Value to EBITDA | -32.16 | -89.37 | -83.48 | -129.05 | 314.55% |
| Return on Equity | -129.8% | -80.3% | -50.2% | -36.3% | -65.84% |
| Total Debt | $119.14M | $119.57M | $119.77M | $123.95M | 4.98% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
